Breaking News

Biogen Appoints Value-Based Medicine VP

May 12, 2014

Rudick bring expertise in MS programs

Richard (Rick) A. Rudick, M.D., has been appointed vice president of Development Sciences, Value-Based Medicine, at Biogen Idec. He reports to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.
Dr. Rudick will lead the newly created Value-Based Medicine Group that focuses on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis (MS). The group emphasizes more evidence-based, individualized treatment options with the goal of improving care.   
Dr. Rudick has played key roles in several MS clinical trials, including the trials of Biogen’s products AVONEX (interferon beta-1a) and TYSABRI (natalizumab). Dr. Rudick joins the company from the Cleveland Clinic, where he served as director of the Mellen Center for Multiple Sclerosis Treatment and Research for nearly 30 years.
“Rick has been a valued partner of the company for more than two decades. Through his years of hands-on clinical experience, he has gained a truly unique understanding of the needs of MS patients,” said Dr. Sandrock. “His vision, expertise and passion bolsters our efforts to create real-world, practical solutions to empower better decision-making and improve the way people live with MS.”

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity